Support your patient’s liver
Hepatic dysfunction impairs liver functions like detoxification, synthesis, and regulation, leading to high mortality in intensive care unit (ICU) patients. Extra Corporeal Liver Support (ECLS) systems aim to support liver detoxification by clearing hepatotoxic molecules from the blood.
Next-Level Liver Support
One of the main problems with Acute Liver Dysfunction (ALD) is auto-intoxication from substances usually metabolized or excreted by the liver, such as bilirubin, bile acids, ammonia, and others. Liver auto-intoxication and systemic hyperinflammation, which often accompanies ALD, can progress to Multi Organ Dysfunction Syndrome (MODS).
CytoSorb® provides liver toxin removal and immunomodulation (to address auto-intoxication and immune dysfunction).
Liver support by CytoSorb
CytoSorb is a unique technology proven to effectively, safely, and simultaneously reduce elevated levels of cytokines and bilirubin, thereby promoting hemodynamic stability and recovery of liver function. And as a bridging therapy, CytoSorb has been shown to be superior and easier to apply compared to conventional albumin dialysis.
Hemoadsorption has a different mode of action than dialysis-based therapies have, effectively removing excessive levels of cytokines and liver toxins. Early attenuation of auto-intoxication (and hyperinflammation) can help as bridging therapy towards liver recovery or transplantation.
-
Removal of:
- Bilirubin
- Cytokines
-
Can lead to:
- Improvement of liver function
- Improved clinical outcome
- Hemodynamic stability
CytoSorb can be used to address a variety of challenges associated with liver dysfunction
Manage liver dysfunction
Liver dysfunction can occur in various settings, such as acute-on-chronic liver failure, post-hepatectomy liver failure (PHLF), and acute liver failure.
CytoSorb is a powerful tool to remove bilirubin and other liver toxins efficiently, and to address systemic hyperinflammation via cytokine removal.
Building a vital bridge with CytoSorb
Reduction of systemic inflammation together with support of excretory liver function is intended to bridge to either recovery or liver transplantation
CytoSorb Therapy can help to manage liver dysfunction:
Effective bilirubin removal
Support of hepatic excretory function
Attenuation of hyperinflammation
Ease of setup and use
Best practice therapy management
-
Patient selection
- Bilirubin > 10 mg/dL
(> 170 µmol/L) - Hepatic encephalopathy
grade ≥ 2 - Acute Liver Failure or
Acute-on-Chronic Liver Failure
grade 2-3 - Onset of liver failure after
surgery or transplantation - Intractable pruritus
- Bilirubin > 10 mg/dL
-
Timing
- Integrate CytoSorb in
hemoperfusion, CRRT or ECMO
- Integrate CytoSorb in
-
Dosing
- Consider changing the adsorber after 8 hours until sufficient stabilization / clinical improvement is seen
Additional Information
- Haselwanter et al., Sci Rep 2024; 14(1):11309
- Turan et al., Biomedicines 2024; 12(1):67
- Riva et al., J Art Orgs 2023; epub
- Popescu et al., J Clin Med 2023; 12(6):2258
- Greimel et al., Ann Intensive Care 2023; 13(1):110
- Tomescu et al., Int J Artif Organs 2021; 4(8):560-564
Voices around the world
Access Healthcare Professionals Area
This area is for Health Care Professionals only and provides reports about clinical experiences gained during the use of CytoSorbents products. The information presented reflects the opinions and procedural techniques of individual physicians and is not intended as medical advice. Physician experience, risks, patient outcomes and results may vary. This content is intended for Health Care Professionals outside the United States and Canada as CytoSorb has not yet been approved or cleared in the United States or Canada for any indication, except under an Emergency Use Authorization (EUA) by the US FDA.